| 2024 | | Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study | 강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁 |
| 2018 | | EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients | 강석윤, 고영화, 박준성, 신승수, 이현우, 정성현, 최용원, 최진혁, 한재호 |
| 2022 | | Evaluation of Prognosis and Metastasis by Immunohistochemical Staining of Rab Coupling Protein Expression in Ovarian Cancer | 조도연 |
| 2007 | | Expression of Epidermal Growth Factor Receptor in hypopharyngeal cancer and Effect of EGF in Progression of hypopharyngeal cancer | 김윤태 |
| 2002 | | Expression of epidermal growth factor receptor(EGFR) and transforming growth factor β1(TGF β1) in airway mucosa of toluene diisocyanate(TDI)-induced asthma patients | 김선신, 박해심, 서유진, 최정희 |
| 2023 | | Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma | 고영화, 박범희, 이현우, 한재호, 함석진 |
| 2019 | | Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer | 고영화 |
| 2021 | | Neurofibromin deficiency causes epidermal growth factor receptor upregulation through the activation of Ras/ERK/SP1 signaling pathway in neurofibromatosis type 1-associated malignant peripheral nerve sheet tumor | 김정현, 박건후, 박은국, 이창근, 정선용 |
| 2015 | | Novel Molecular Mechanism of Bcl-xL in EGFR-mediated Ras Signaling | 박호진 |
| 1999 | | Signal Transduction System of Experimentally Induced Cholesteatoma in the Mongolian Gerbil | 박기현, 박홍준, 황성철 |
| 2013 | | The Role of Bcl-xL and EGFR in the Malignant Progression of Neurofibromatosis type 1 | 이수진 |
| 2023 | | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial | 최진혁 |
